CD274 and non-small cell lung carcinoma: Chemo-immunotherapy combo benefit regardless of PD-L1 status. Pembrolizumab plus pemetrexed-platinum remains a standard-of-care therapy for patients with newly diagnosed metastatic nonsquamous NSCLC